» Articles » PMID: 15306174

Hepatic Production of VLDL1 but Not VLDL2 is Related to Insulin Resistance in Normoglycaemic Middle-aged Subjects

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2004 Aug 13
PMID 15306174
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin resistance is probably the defining feature of the metabolic syndrome and is an important determinant of plasma triglyceride (TG) concentrations. We sought to investigate whether insulin resistance influenced the metabolism of VLDL1 (Sf 60-400) and VLDL2 (Sf 20-60). Sixteen (eight men, eight women) middle-aged, normoglycaemic subjects participated. VLDL1and VLDL2 apolipoprotein (apo) B metabolism was followed using a deuterated leucine tracer and insulin resistance was estimated using homeostasis model assessment (HOMA). HOMA-estimated insulin resistance (HOMAIR) significantly and strongly correlated with the VLDL1 production rate (r = 0.69, P < 0.01) and VLDL1 apo B pool size (r = 0.59, P = 0.02), but these relationships were not evident for VLDL2. Conversely, HOMAIR was not significantly related to the fractional rate of transfer of VLDL1 to VLDL2 but was significantly related to the fractional rate of transfer from VLDL2 to IDL (r = 0.61, P = 0.01). HOMAIR was not significantly related to the fractional rate of direct catabolism for either VLDL1 or VLDL2. These results suggest a role for insulin resistance in the determination of hepatic VLDL1 production and highlight the independent regulation of VLDL1 and VLDL2 metabolism.

Citing Articles

Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.

Hirano T J Diabetes Investig. 2025; 16(3):370-383.

PMID: 39778086 PMC: 11871407. DOI: 10.1111/jdi.14398.


Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol could be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 Diabetes.

Hirano T J Atheroscler Thromb. 2024; 32(2):253-264.

PMID: 39231648 PMC: 11802249. DOI: 10.5551/jat.65164.


Walking the VLDL tightrope in cardiometabolic diseases.

Kim M, Zheng Z Trends Endocrinol Metab. 2024; 36(3):278-291.

PMID: 39191606 PMC: 11861388. DOI: 10.1016/j.tem.2024.07.020.


Hepatic insulin resistance and muscle insulin resistance are characterized by distinct postprandial plasma metabolite profiles: a cross-sectional study.

Gijbels A, Erdos B, Trouwborst I, Jardon K, Adriaens M, Goossens G Cardiovasc Diabetol. 2024; 23(1):97.

PMID: 38493102 PMC: 10944619. DOI: 10.1186/s12933-024-02188-0.


Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial.

Gorji M, Alaei-Shahmiri F, Darban Hosseini Amirkhiz G, Sezavar S, Malek M, Khamseh M Arch Iran Med. 2024; 26(6):290-299.

PMID: 38310429 PMC: 10685836. DOI: 10.34172/aim.2023.45.